Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-κB/Rel transcription factors

Blood

Volumn 94, Issue 12, 1999, Pages 4060-4066

  Romano, Maria Fiammetta ^b   Lamberti, Annalisa ^b   Bisogni, Rita ^b   Garbi, Corrado ^b   Pagnano, Antonio M ^b   Auletta, Pasquale ^b   Tassone, Pierfrancesco ^b   Turco, Maria Caterina ^a   Venuta, Salvatore ^b  

^a Dipto di Biochim e B M   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL SURVIVAL; DRUG MECHANISM; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; MYELODYSPLASIA; NONHUMAN; PRIORITY JOURNAL;

EID: 0032795848     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.12.4060.424k23_4060_4066     Document Type: Article

References (52)

1. Mehta MP: Protection of normal tissues from the cytotoxic effects of radiation therapy: Focus on amifostine. Semin Radiat Oncol 4:14, 1998
2. Douay L, Hu C, Giarratana MC, Gorin NC: Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukemic effects. Eur J Cancer 31A:S14, 1995
3. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101, 1996
4. Schiller JH, Storer B, Berlin J, Wittenkeller J, Larson M, Pharo L, Larson M, Berry W: Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: A report of high response rates and prolonged survival. J Clin Oncol 14:1913, 1996
5. Fichtner I, Lemm M, Becker M, Berthold F: Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas. Anticancer Drugs 8:174, 1997
6. Pierelli L, Scambia G, Fattorossi A, Bonanno G, Battaglia A, Perillo A, Menichella G, Panici PB, Leone G, Mancuso S: In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: Haematoprotection acts as a drug-specific progenitor rescue. Br J Cancer 78:1024, 1998
7. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL: Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 23:58, 1996
8. Fetscher S, Mertelsmann R: Supportive care in hematologic malignancies. Curr Opin Hematol 5:271, 1998
9. Griggs JJ: Reducing the toxicity of anticancer therapy: New strategies. Leuk Res 22:S27, 1998
10. Kurbacher CM, Mallmann PK: Chemoprotection in anticancer therapy: The emerging role of amifostine (WR-2721). Anticancer Res 18:2203, 1998
11. Foster-Nora JA, Siden R: Amifostine for protection from antineo-plastic drug toxicity. Am J Health Syst Pharm 54:787, 1997
12. Links M, Lewis C: Chemoprotectants: A review of their clinical pharmacology and therapeutic efficacy. Drugs 57:293, 1999
13. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R: Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90:3364, 1997
14. Capizzi RL: Clinical status and optimal use of amifostine. Oncology 13:47, 1999
15. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL: Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia 12:1596, 1998
16. Beg AA, Baltimore D: An essential role for NF-κB in preventing TNF-α induced cell death. Science 274:782, 1996
17. Wang C-I, Mayo MW, Baldwin AS Jr: TNF- and cancer therapy induced apoptosis: Potentiation by inhibition of NF-κB. Science 274:784, 1996
18. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNF-α-induced apoptosis by NF-κB. Science 274:787, 1996
19. Liu Z, Hsu H, Goeddel DV, Karin M: Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87:565, 1996
20. Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, FitzGerald MJ, Rothstein TL, Sherr DH, Sonenshein GE: Inhibition of NF-κB/Rel induces apoptosis of murine B cells. EMBO J 15:4682, 1996
21. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F, Defrance T, Bonelli P, Tuccillo MF, Turco MC, Venuta S: Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 92:990, 1998
22. Van Antwerp DJ, Martin SJ, Verma IM, Green DR: Inhibition of TNF-induced apoptosis by NF-κB. Trends Cell Biol 8:107, 1998
23. Ghosh S, May MJ, Kopp EB: NF-κB and Rel proteins: Evolutionary conserved mediators of immune response. Annu Rev Immunol 16:225, 1998
24. Zong WX, Bash J, Gelinas C: Rel blocks anti-Fas- and TNFα-induced apoptosis and intact Rel transactivation domain is essential for this effect. Cell Death Differ 5:963, 1998
25. Greenberger JS, Gans P, Davisson P, Moloney W: In vitro induction of continuous acute promyelocytic leukemia cell lines by Friend or Abelson murine leukemia virus. Blood 53:987, 1979
26. Takenaka K, Nagafuji K, Mizuno S, Miyamoto T, Makino S, Gondo H, Okamura T, Niho Y: In vitro expansion of hematopoietic progenitor cells induces functional expression of Fas antigen (CD95). Blood 88:2871, 1996
27. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Ricciardi CA: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271, 1991
28. Nicholson DW, Ali A, Thornberry NA: Identification and inhibition of the ICE-CED-3 protease necessary for mammalian apoptosis. Nature 376:37, 1995
29. Romano MF, Lamberti A, Petrella A, Bisogni R, Tassone P, Formisano S, Venuta S and Turco MC: IL-10 inhibits nuclear factor-κB/ Rel nuclear activity in CD3-stimulated human peripheral T lymphocytes. J Immunol 156:2119, 1996
30. Goldring EP, Narayanan R, Lagadec P, Jeannin J-F: Transcriptional inhibition of the inducible nitric oxide synthase gene by competitive binding of NF-κB/Rel proteins. Biochem Biophys Res Commun 209:73, 1995
31. Sharma HW, Perez JR, Higgins-Sochaski K, Hsiao R, Narayanan R: Transcription factors decoy approach to decipher the role of NF-κB in oncogenesis. Anticancer Res 16:61, 1996
32. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaned Y, Higaki J, Ogihara T: In vivo transfection of cis element "decoy" against nuclear factor-κB binding site prevents myocardial infarction. Nat Med 8:894, 1997
33. Khaled AR, Butfiloski EJ, Sobel ES, Schiffenbauer J: Use of phosphorothioate-modified oligodeoxynucleotides to inhibit NF-κB expression and lymphocyte function. Clin Immunol Immunopathol 86:170, 1998
34. Chen F, Castranova V, Shi X, Demers LM: New insights into the role of NF-κB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45:7, 1999
35. Waddick KG, Uckun FM: Innovative treatment programs against cancer: II. NF-κB as a molecular target. Biochem Pharmacol 57:9, 1999
36. Wang CY, Cusack JC, Liu R, Baldwin AS Jr: Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 5:412, 1999
37. Pyatt DW, Stillman WS, Yang Y, Gross S, Zheng J, Irons RD: An essential role for NF-κB in human CD34+ bone marrow cell survival. Blood 93:3302, 1999
38. Jans DA, Hassan G: Nuclear targeting by growth factors, cytokines, and their receptors: A role in signaling? Bioassays 20:400, 1998
39. Mattai JW, Englmeier L: Nucleocytoplasmic transport: The soluble phase. Annu Rev Biochem 67:265, 1998
40. Zhang MY, Harhaj EW, Bell L, Sun SC, Miller BA: Bcl-3 expression and nuclear translocation are induced by granulocyte-macrophage colony-stimulating factor and erythropoietin in proliferating human erythroid precursors. Blood 92:1225, 1998
41. Besancon F, Atfi A, Gespach C, Cayre YE, Bourgeade MF: Evidence for a role of NF-κB in the survival of hematopoietic cells mediated by interleukin 3 and oncogenic TEL/platelet-derived growth factor receptor β fusion protein. Poc Natl Acad Sci USA 95:8081, 1998
42. de Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nuñez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278:687, 1997
43. Songyang Z, Baltimore D, Cantley LC, Kaplan DR, Franke TF: Interleukin 3-dependent survival by the Akt protein kinase. Poc Natl Acad Sci USA 24:11345, 1997
44. Blume-Jense P, Janknecht R, Hunter T: The kit receptor promotes cell survival via activation of PI3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol 8:779, 1998
45. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW: Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Poc Natl Acad Sci USA 94:10057, 1997
46. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin ASR: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 281:1680, 1998
47. Wu MX, Ao Z, Prasad KVS, Wu R, Schlossman SF: 1EX-1L, an apoposis inhibitor involved in NF-κB-mediated cell survival. Science 281:998, 1998
48. Grumont RJ, Rourke IJ, Gerondakis S: Rel-dependent induction of AI transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 13:400, 1999
49. Zong W-X, Edelstein LC, Chen C, Bash J, Gélins C: The pro-survival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev 13:382, 1999
50. Opipari AW Jr, Hu HM, Yabkowitz R , Dixit VM: The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem 267:12424, 1992
51. Dimmeler S, Haendeler J, Sause Zeiher M: Nitric oxide inhibits APO-1/Fas-mediated cell death. Cell Growth Differ 9:415, 1998
52. Sciorati C, Rovere P, Ferrarini M, Heltai S, Manfredi AA, Clementi E: Autocrine nitric oxide modulates CD95-induced apoptosis in gammadelta T lymphocytes. J Biol Chem 272:23211, 1997